Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine Development
5 Articles
5 Articles
Psyence BioMed Welcomes U.S. Administration's Latest Action to Accelerate Ibogaine Development
Company says growing federal commitment to ibogaine aligns directly with the pharmaceutical development and manufacturing platform Psyence BioMed has built NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) — Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived psychedelic compounds for clinical research and […]
The Toronto Star
Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine Development
NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived psychedelic compounds for clinical research and therapeutic applications, today welcomed President…
Coverage Details
Bias Distribution
- 80% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
